Outcomes and Adverse Events in Patients with Cancer after Diagnosis of Immunotherapy-Associated Diabetes Mellitus: A Retrospective Cohort Study.

Eva Duvalyan, Sam Brondfield, Robert J Rushakoff, Mark S Anderson, Zoe Quandt

Abstract read

In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eva DuvalyanSchool of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.

Sam BrondfieldDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.

Robert J RushakoffDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.

Mark S AndersonDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.

Zoe QuandtDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.

Funding

Diabetes-Docs: Physician-Scientist Career Development Program (DiabDocs)K12DK133995 · NIDDK · STANFORD UNIVERSITY · PI LINDA A DIMEGLIO, David Matthew Maahs · 2022 to 2026

$16.0M

NIDDK NIH HHS K12 DK133995

6 · The paper itself

Abstract

Immune checkpoint inhibitor (CPI)-induced diabetes mellitus (CPI-DM) is a rare immune-related adverse event (irAE). Patients and providers fear that continuing CPIs puts patients at risk for additional irAEs and thus may discontinue therapy. Currently, there are little data to inform this decision. Therefore, this study aims to elucidate whether discontinuing CPIs after diagnosis of CPI-DM impacts the development of future irAEs and cancer outcomes such as progression and death. Patients who developed CPI-DM during cancer treatment at UCSF from 1 July 2015 to 5 July 2023 were analyzed for cancer outcomes and irAE development. Fisher's exact tests, Student

Indexed as

autoimmunitycheckpoint blockadediabetes mellitusimmune monitoringimmune toleranceimmune toxicitymetabolism

Identifiers

PMID38730614

DOI10.3390/cancers16091663

PMCPMC11083325

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.